Latest Kynam Capital Management, LP Stock Portfolio
Kynam Capital Management, LP Performance:
2025 Q1: -20.47%YTD: -20.47%2024: 31%
Performance for 2025 Q1 is -20.47%, and YTD is -20.47%, and 2024 is 31%.
About Kynam Capital Management, LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Kynam Capital Management, LP reported an equity portfolio of $1.2 Billions as of 31 Mar, 2025.
The top stock holdings of Kynam Capital Management, LP are NTRA, PCVX, CLDX. The fund has invested 13.9% of it's portfolio in NATERA INC and 10.2% of portfolio in VAXCYTE INC.
The fund managers got completely rid off 2SEVENTY BIO INC (TSVT), PROTAGONIST THERAPEUTICS INC (PTGX) and ACELYRIN INC stocks. They significantly reduced their stock positions in LIQUIDIA CORPORATION (LQDA), DYNAVAX TECHNOLOGIES CORP (DVAX) and NATERA INC (NTRA). Kynam Capital Management, LP opened new stock positions in LEGEND BIOTECH CORP, NURIX THERAPEUTICS INC (NRIX) and GERON CORP (GERN). The fund showed a lot of confidence in some stocks as they added substantially to TYRA BIOSCIENCES INC (TYRA), RELAY THERAPEUTICS INC (RLAY) and CLIMB BIO INC (ELYM).
The top stock holdings of Kynam Capital Management, LP are NTRA, PCVX, CLDX. The fund has invested 13.9% of it's portfolio in NATERA INC and 10.2% of portfolio in VAXCYTE INC.
The fund managers got completely rid off 2SEVENTY BIO INC (TSVT), PROTAGONIST THERAPEUTICS INC (PTGX) and ACELYRIN INC stocks. They significantly reduced their stock positions in LIQUIDIA CORPORATION (LQDA), DYNAVAX TECHNOLOGIES CORP (DVAX) and NATERA INC (NTRA). Kynam Capital Management, LP opened new stock positions in LEGEND BIOTECH CORP, NURIX THERAPEUTICS INC (NRIX) and GERON CORP (GERN). The fund showed a lot of confidence in some stocks as they added substantially to TYRA BIOSCIENCES INC (TYRA), RELAY THERAPEUTICS INC (RLAY) and CLIMB BIO INC (ELYM).
Kynam Capital Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Kynam Capital Management, LP made a return of -20.47% in the last quarter. In trailing 12 months, it's portfolio return was -15.56%.
New Buys
| Ticker | $ Bought |
|---|---|
| legend biotech corp | 20,697,300 |
| nurix therapeutics inc | 9,504,000 |
| geron corp | 5,818,650 |
| design therapeutics inc | 3,489,510 |
| urogen pharma ltd | 276,500 |
New stocks bought by Kynam Capital Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| tyra biosciences inc | 353 |
| relay therapeutics inc | 206 |
| climb bio inc | 91.41 |
| cullinan therapeutics inc | 86.68 |
| vera therapeutics inc | 64.62 |
| sutro biopharma inc | 49.43 |
| beam therapeutics inc | 43.39 |
| viridian therapeutics inc | 41.3 |
Additions to existing portfolio by Kynam Capital Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| liquidia corporation | -72.03 |
| dynavax technologies corp | -60.05 |
| natera inc | -42.26 |
| biocryst pharmaceuticals inc | -1.73 |
Kynam Capital Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| 2seventy bio inc | -17,504,200 |
| acelyrin inc | -2,660,730 |
| protagonist therapeutics inc | -15,084,600 |
Kynam Capital Management, LP got rid off the above stocks
Sector Distribution
Kynam Capital Management, LP has about 90.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 90.3 |
| Others | 9.7 |
Market Cap. Distribution
Kynam Capital Management, LP has about 14.1% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 40.3 |
| MID-CAP | 30.1 |
| LARGE-CAP | 14.1 |
| UNALLOCATED | 14 |
| MICRO-CAP | 1.4 |
Stocks belong to which Index?
About 71.2% of the stocks held by Kynam Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 71.2 |
| Others | 28.8 |
Kynam Capital Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Kynam Capital Management, LP
Kynam Capital Management, LP has 31 stocks in it's portfolio. About 72.7% of the portfolio is in top 10 stocks. PCVX proved to be the most loss making stock for the portfolio. LQDA was the most profitable stock for Kynam Capital Management, LP last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AMRN | amarin corp plc | 0.47 | 12,414,600 | 5,563,000 | unchanged | 0.00 | ||
| BCRX | biocryst pharmaceuticals inc | 5.63 | 8,928,520 | 66,963,900 | reduced | -1.73 | ||
| BEAM | beam therapeutics inc | 4.13 | 2,518,170 | 49,179,900 | added | 43.39 | ||
| BNR | burning rock biotech ltd | 0.37 | 994,883 | 4,379,690 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 1.49 | 2,338,630 | 17,703,400 | added | 86.68 | ||
| CLDX | celldex therapeutics inc new | 9.91 | 6,500,000 | 117,975,000 | added | 28.35 | ||
| COGT | cogent biosciences inc | 4.58 | 9,105,000 | 54,539,000 | unchanged | 0.00 | ||
| CRBU | caribou biosciences inc | 0.25 | 3,269,150 | 2,985,060 | added | 35.87 | ||
| DSGN | design therapeutics inc | 0.29 | 904,017 | 3,489,510 | new | |||
| DVAX | dynavax technologies corp | 2.86 | 2,620,800 | 33,991,700 | reduced | -60.05 | ||
| ELYM | climb bio inc | 0.11 | 1,047,000 | 1,277,340 | added | 91.41 | ||
| GERN | geron corp | 0.49 | 3,659,530 | 5,818,650 | new | |||
| IMCR | immunocore hldgs plc | 4.23 | 1,695,580 | 50,307,700 | added | 38.35 | ||
| IRWD | ironwood pharmaceuticals inc | 0.72 | 5,822,940 | 8,559,720 | added | 24.27 | ||
| LQDA | liquidia corporation | 0.78 | 633,802 | 9,348,580 | reduced | -72.03 | ||
| NRIX | nurix therapeutics inc | 0.80 | 800,000 | 9,504,000 | new | |||
| NTRA | natera inc | 13.87 | 1,167,570 | 165,106,000 | reduced | -42.26 | ||
| PCVX | vaxcyte inc | 10.15 | 3,200,000 | 120,832,000 | added | 36.94 | ||
| PTGX | protagonist therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| RLAY | relay therapeutics inc | 0.67 | 3,063,290 | 8,025,820 | added | 206 | ||